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Abstract
BACKGROUND
Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the
metabolic syndrome (MetS) and is characterized by steatosis in the absence of
significant alcohol consumption. However, MetS and significant alcohol intake
coexist in certain individuals which may lead to the development of BAFLD.
AIM
To assess the clinical characteristics of patients with both alcoholic and NAFLD
(BAFLD) in a large cohort in the United States.
METHODS
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Adults from the National Health and Nutrition Examination Survey between
2003-2014 were included. NAFLD was diagnosed based on elevated alanine
aminotransferase (ALT) and being overweight or obese in the absence of other
liver diseases. BAFLD patients met the criteria for NAFLD but also had either
MetS or type 2 diabetes and consumed excessive amounts of alcohol. Univariable
and multivariable analysis were performed to assess differences between NAFLD
and BAFLD and to compare severity based on a validated fibrosis score (FIB4
index).
RESULTS
The prevalence of NAFLD was at 25.9% (95%CI; 25.1-26.8) and that of BAFLD
was 0.84% (0.67, 1.02) which corresponds to an estimated 1.24 million Americans
affected by BAFLD. Compared to NAFLD, patients with BAFLD were more
likely to be male, smokers, have higher ALT, aspartate aminotransferase,
triglycerides, and lower platelets; P < 0.01 for all. More importantly, after
adjusting for MetS components, BAFLD patients were significantly more likely to
have advanced fibrosis [adjusted OR (95%CI) based on FIB4 index > 2.67 was 3.2
(1.4, 7.0), P = 0.004].
CONCLUSION
A significant percentage of the American general population is afflicted by
BAFLD and these patients tend to have more advanced liver fibrosis.
Key words: Non-alcoholic fatty liver disease; Alcoholic liver disease; Fatty liver disease
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Core tip: Using the National Health and Nutrition Examination Survey dataset, we
studied a new classification of fatty liver disease that we believe is due to risk factors for
both non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease occurring in
the same individual. We propose to call this entity Both Alcoholic and NAFLD
(BAFLD). As most of the risk factors that lead to BAFLD are potentially modifiable,
understanding their reciprocal association and combined effect on the liver may aid in
understanding, treating, and preventing BAFLD.
Citation: Khoudari G, Singh A, Noureddin M, Fritze D, Lopez R, Asaad I, Lawitz E, Poordad
F, Kowdley KV, Alkhouri N. Characterization of patients with both alcoholic and
nonalcoholic fatty liver disease in a large United States cohort. World J Hepatol 2019; 11(10):
710-718
URL: https://www.wjgnet.com/1948-5182/full/v11/i10/710.htm
DOI: https://dx.doi.org/10.4254/wjh.v11.i10.710
INTRODUCTION
Fat accumulation in the liver, known as fatty liver disease, is a major cause of chronic
liver disease worldwide[1]. There are two main classifications of fatty liver disease:
alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD). The well-
accepted threshold values of alcohol consumption thought to contribute to ALD are
30 g/d for men and 20 g/d for women[2,3]. NAFLD, on the other hand, is considered as
the hepatic manifestation of the metabolic syndrome (MetS)[4] and is characterized by
the presence of liver steatosis in the absence of other causes of fatty liver disease,
particularly significant alcohol consumption. Recently, in the general population, the
prevalence of obesity and MetS has been rising[5]; this increase presumably positively
correlates  with  cases  of  NAFLD.  Globally,  NAFLD  is  estimated  to  afflict
approximately 25.24% (95%CI: 22.10-28.65) of the population[6],  and is on track to
becoming the leading cause of liver transplantation in the near future. Similarly, the
prevalence  of  ALD is  on  the  rise.  Currently,  it  affects  nearly  8% of  the  general
population in the United States. Alcohol appears to differentially induce toxic effects
on the liver based on sex: It takes approximately twice the volume of alcohol and a
longer  duration  of  alcohol  consumption  for  men  to  develop  ALD  compared  to
women[7]. In men, ethnicity appears to affect rates and outcomes of alcoholic cirrhosis:
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Incidence is highest in African-Americans followed by Hispanics then Caucasians;
however, Hispanic males have the highest mortality rates from alcoholic cirrhosis[8,9].
In a substantial proportion of the population, the risk factors that contribute to each
of the two main types of fatty liver disease coexist within a given individual. Alcohol
consumption sensitizes the liver to damage induced by MetS and vice versa; this
could result in concurrent ALD and NAFLD in the same liver. We propose to call this
scenario  both  alcoholic  and  NAFLD  (BAFLD).  We  also  believe  that  due  to  the
presence of risk factors for both ALD and NAFLD, patients with BAFLD are at higher
risk of advanced fibrosis (AF) and complications related to end-stage liver disease.
Studies describing the combined effect of alcohol consumption and MetS on hepatic
steatosis are scarce. MetS and excess alcohol consumption are likely responsive to
modifiable dietary and lifestyle factors;  therefore, understanding their reciprocal
interaction and combined effect on the liver might lead to a better understanding of
BAFLD pathogenesis as well as strategies for treatment and prevention[10]. The aim of
this study was to determine and compare the prevalence and clinical characteristics of
BAFLD to NAFLD in a large cohort of subjects in the United States.
MATERIALS AND METHODS
Subjects
All adult (18+ years) subjects who participated in the National Health and Nutrition
Examination  Survey  (NHANES)  during  2003-2014  cycles  were  identified  and
assessed. The NHANES is a survey program conducted by the National Center for
Health  Statistics  (NCHS),  which  is  part  of  the  Centers  for  Disease  Control  and
Prevention (CDC). The program is designed to assess the health and nutritional status
of adults and children in the United States. It began in the early 1960s and became a
continuous  program in  1999.  It  examines  a  sample  of  5000  persons  a  year  from
different counties across the United States representing the United States population
of all  ages.  The survey includes interview questionnaires,  standardized physical
examination,  and laboratory  tests  from blood samples  collected  at  examination
centers  and  analyzed  at  a  central  laboratory.  The  survey  was  approved  by  the
Institutional Review Board at the Center for Disease Control and Prevention, and
informed consent was obtained from all participants.
Diagnosis of NAFLD was made based on elevated alanine aminotransferase (ALT)
(> 30 U/L in males and > 19 in females) and being overweight or obese [body mass
index (BMI) ≥ 25 kg/m2) in the absence of other causes of chronic liver disease (viral
hepatitis, autoimmune liver disease, metabolic liver disease, total parenteral nutrition
and medications etc.) Patients with BAFLD met the criteria for NAFLD but also had
either MetS or type 2 diabetes and consumed excessive amounts of alcohol defined as
≥ 3 drinks/d for men and ≥ 2 drinks/d for women. The following patients were
excluded; reported use of hepatotoxic medications, hepatitis viral infection, missing
ALT,  missing  BMI,  no  alcohol  intake  information,  missing  diabetes  status,  and
missing information on MetS components. MetS was defined as central Obesity plus
at least 2 of the following: diabetes, hypertension, hypertriglyceridemia or low high-
density lipoprotein cholesterol (HDL).
Demographic  variables  including age,  gender,  ethnicity,  waist  circumference,
average drinks a day, smoking status, BMI, central obesity, hypertension, diabetes,
triglyceride (TG), HDL, MetS, and other variables were also collected. Laboratory
parameters including aspartate aminotransferase (AST), ALT, alkaline phosphatase,
platelets, albumin, bilirubin, lipid profile including TG and hemoglobin A1c (HbA1C)
were also measured.
To assess  for  the  presence  of  AF in  NAFLD and BAFLD,  a  non-invasive  liver
fibrosis  score,  Fibrosis-4  (FIB-4)  index,  was calculated using age,  AST,  ALT and
platelet count.
Outcomes
The primary outcome was to assess the prevalence and clinical characteristics of
NAFLD and BAFLD. The secondary outcome was to evaluate the prevalence of AF in
patients with NAFLD and BAFLD.
Statistical analysis
Data is presented as the mean ± SE or un-weighted frequency (%). The prevalence of
NAFLD and BAFLD was assessed by calculating the percent of participants meeting
the definitions of each; the corresponding 95%CIs are reported. A subgroup analysis
was performed in subjects  with either  of  the two liver  diseases.  The unadjusted
analysis  was implemented to evaluate differences between NAFLD and BAFLD;
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continuous variables were compared using t-tests, and categorical variables were
compared using Rao-Scott chi-square tests. A multivariable regression analysis was
performed to compare disease severity between the BAFLD and NAFLD groups, after
adjusting for  diabetes  and other  components  of  the metabolic  syndrome.  Linear
regression was used to model FIB-4 score while logistic regression was used to model
the presence of suspected AF based on these scores.
All analyses were performed using SAS survey procedures (version 9.4, The SAS
Institute, Cary, NC, United States), which account for the complex sampling design of
NHANES and appropriately weight participants in statistical models. The full sample
MEC exam weights were used in all  analyses;  weights for combined cycles were
constructed following the guidelines provided in the NHANES analytic guidelines.
RESULTS
Prevalence of BAFLD in United States adult population
A total  of  20939  subjects  met  the  inclusion  criteria  during  the  2003-2014  cycles.
Overall, the prevalence of NAFLD was 25.9% (95%CI: 25.1-26.8), and that of BAFLD
was  0.84%  (95%CI:  0.67-1.02),  which  corresponds  to  an  estimated  1.24  million
Americans affected by BAFLD as shown in Table 1.
Patient characteristics: The descriptive characteristics of the study participants are
shown in Table 2. Compared to patients with NAFLD, patients with BAFLD were
more likely to be males, but there were no significant differences in the mean age
between the two groups (43.8 vs 44.5 years; P = 0.34). The BAFLD population had
approximately 2.5 times more current smokers than NAFLD group and they also had
approximately 16 times a greater number of drinks/d. Given the fact that we used
MetS  and  diabetes  mellitus  type  2  (DM2)  as  part  of  the  definition  of  BAFLD,
components of the MetS were more common in the BAFLD cohort.  For example,
central obesity was also more prevalent in BAFLD patients. In addition, we found
significantly  higher  percentage  of  MetS  in  BAFLD  group  compared  to  NAFLD
population, with high prevalence of HTN, DM, hypertriglyceridemia and low HDL, P
< 0.001 for all. Patients with BAFLD were more likely to have significantly higher
ALT,  AST,  gamma  glutamyl  transferase  (GGT).  Patients  with  BAFLD  also  had
significantly higher cholesterol  and HbA1C than NAFLD patients.  Interestingly,
compared to NAFLD patients, those with BAFLD had lower platelet counts.
Prevalence of AF in patients with NAFLD and BAFLD
Based on FIB-4 index of 2.67 or higher, patients with BAFLD were found to have
significantly higher prevalence of AF compared to the NAFLD group, (7.1% ± 2.5 in
the BAFLD group vs 1.7% ± 0.22 in the NAFLD group, P = 0.045) as seen in Figure 1.
Even after adjusting for all the components of MetS, subjects with BAFLD had 3.2
times higher odds of having AF than those with NAFLD [OR (95%CI) for FIB-4 > 2.67
= 3.2 (1.4, 7.0, P = 0.004)].
DISCUSSION
To  the  best  of  our  knowledge,  the  current  study  provides  novel  data  on  the
prevalence  and  clinical  characteristics  of  BAFLD  in  the  United  States  adult
population. The main findings of our study are the following: (1) BAFLD is common
in the United States with an estimated 1.24 million Americans being affected; (2)
Compared to NAFLD, patients with BAFLD were more likely to be male and active
smokers; (3) They also have higher ALT (53.1 vs 38.2 U/L), AST (43.3 vs 31.2 U/L),
and lower platelet counts (243 vs 261 K/uL) (P < 0.05 for all); and (4) The prevalence
of AF was also significantly higher in patients with BAFLD than subjects with NAFLD
with an adjusted OR of having AF being 3.2 (1.4, 7.0) based on the FIB-4 index.
Several studies have highlighted the strong bidirectional association between MetS
components and NAFLD[4,11,12]. Obesity is a principle risk factor for both NAFLD and
MetS.  NAFLD  was  reported  to  occur  in  >  95%  of  patients  with  severe  obesity
undergoing  bariatric  surgery[13,14].  Between  1980  and  2014,  the  World  Health
Organization  (WHO)  reported  a  doubling  of  obesity,  with  39%  of  adults  being
considered overweight in 2014. In light of this, it is unsurprising that the prevalence of
NAFLD is estimated to be close to 25% of the adult population[4,15], which is consistent
with our results.
Nearly 70% of the adult population worldwide is estimated to consume alcohol; the
highest consumption levels are found in the developed world, particularly Europe
and North America[16]. This suggests that the prevalence of ALD in the United States
WJH https://www.wjgnet.com October 27, 2019 Volume 11 Issue 10
Khoudari G et al. Both alcoholic and nonalcoholic fatty liver disease
713
Table 1  Prevalence of non-alcoholic fatty liver disease, alcoholic liver disease and both
alcoholic and non-alcoholic fatty liver disease
Liver disease Unweighted frequency Weighted frequency Prevalence (95%CI)
NAFLD 5351 38151562 25.9 (25.1, 26.8)
BAFLD 170 1243289 0.84 (0.67, 1.02)
ALD 81 590979 0.40 (0.28, 0.52)
Unweighted population total: 20939; Weighted population total: 147169551. NAFLD: Non-alcoholic fatty liver
disease; BAFLD: Both alcoholic and non-alcoholic fatty liver disease; ALD: Alcoholic liver disease.
would likely be high as well. Diseases of excess alcohol largely affect men, which
could be explained by the fact that men drink more frequently, in larger quantities,
and have fewer  abstainers  than women[16].  However,  females  are  more prone to
alcohol-related liver injury upon consuming lesser quantities of alcohol for shorter
durations. Determining the relative clinical contributions of alcohol consumption and
MetS to fatty liver disease is difficult, especially when both risk factors are present in
the same patient. Indeed, it is well known that patients with NAFLD can consume
higher amounts of alcohol than previously thought[17]. Obesity/MetS and excessive
alcohol consumption may coexist in a significant proportion, affecting the liver in
ways that may lead to the development of BAFLD.
Although, there are data addressing the effect of alcohol or obesity on liver[18-21], the
interaction between alcohol consumption and obesity/MetS and their effect on liver
biochemical  variables  are  not  well  characterized.  Age,  sex,  and  ethnicity  affect
NAFLD prevalence; the likelihood of men having NAFLD is two times higher than
women[6]. In the present study, patients with BAFLD were more likely to be males
(75.8% ± 3.9% vs  46.9% ± 0.87%) and smokers (45.3% vs  17.6%) than patients with
NAFLD alone. This is likely due to the larger number of males with alcoholic liver
disease and high percentage of male smokers.
Furthermore, our data demonstrate that patients with BAFLD, when compared to
the NAFLD group, had higher liver enzymes and lower platelets counts, suggesting
more advanced liver disease in these patients. Our results are in concordance with
previous  studies  that  implied that  the  effect  of  alcohol  consumption on hepatic
steatosis, as measured by the examination of serum liver enzymes, increased with
increasing BMI[22-25]. Hepatic steatosis was only found in 16% of lean controls in the
Dionysos study in Northern Italy; however, this prevalence was increased to 46% in
subjects with an alcohol intake > 60 g/d and to 76% in the obese participants[26].
Notably, in our study, BAFLD patients had three-times the risk of AF than the
NAFLD group. This likely suggests that the combined effect of ALD and NAFLD
have a synergistic unfavorable impact on hepatic fibrosis. The mechanism underlying
this interaction is not known. Few small studies have assessed the effect of alcohol
consumption on the underlying hepatic histopathology in subjects diagnosed with
NAFLD. In a cohort of 112 patients with liver biopsies, Petersen et al[27] found that the
only positive association between weight and fatty liver wass in patients who were
overweight and had moderate alcohol consumption.  Ekstedt et  al[28]  found faster
fibrosis progression in NAFLD patients who consumed alcohol in moderate amounts.
Binge drinking and insulin resistance have been reported to be independent risk
factors associated with the progression of fibrosis over a mean of 13.8-year interval. In
1997, Naveau et al[29] and Raynard et al[30] showed that BMI is positively associated
with AF in ALD. Obesity may sensitize an individual to alcohol-induced liver injury
at a much lower dose. We estimated 1.24 million Americans might be affected by
BAFLD with the concomitant three-fold increase in AF; therefore, this is a significant
public health issue with important policy implications.
Our results showed significantly higher blood TG (268 mg/dL vs 186 mg/dL) in
patients with BAFLD compare to patients with NAFLD. We propose that there may
be a combined additive or synergistic effect of alcohol and NAFLD on triglycerides.
NAFLD is characterized by increases in TG, very-low-density lipoprotein (LDL),
apolipoprotein B to apolipoprotein A1 ratio, and small dense LDL in conjunction with
low HDL[31].  Similarly,  alcohol  consumption is  a  well-known cause of  secondary
hypertriglyceridemia and it may exaggerate hypertriglyceridemia in primary lipid
disorders[32,33]. Therefore, BAFLD patients may have increased cardio vascular disease
(CVD) risk and mortality compared to patients with NAFLD. However, these findings
should be interpreted with caution given the fact that MetS and DM2 were included
in the definition of BAFLD.
Our study has several  limitations.  It  was a cross-sectional  study using a large
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Table 2  Demographics and clinical variables
Factor (unit) NAFLD BAFLD P value
Gender, % ± SE < 0.001
Male 46.9 ± 0.872 75.8 ± 3.91
Current smoker, % ± SE 17.6 ± 0.662 45.3 ± 5.21 < 0.001
BMI, mean ± SE 32.4 ± 0.13 33.1 ± 0.56 < 0.001
Overweight (BMI 25+), % ± SE 100.0 ± 0.00 100.0 ± 0.00
Obese (BMI 30+), % ± SE 57.6 ± 1.04 64.4 ± 4.7 0.18
Severely obese (BMI 40+), % ± SE 11.1 ± 0.63 12.3 ± 3.2 0.7
Waist circumference (cm), mean ± SE 106.5 ± 0.322 111.9 ± 1.31 < 0.001
Average number of drinks/d, mean ± SE 0.26 ± 0.012 4.3 ± 0.221 < 0.001
Central obesity, % ± SE 79.2 ± 0.862 92.3 ± 2.51 < 0.001
HTN (MS), % ± SE 43.5 ± 1.032 74.7 ± 3.81 < 0.001
Diabetes (MS), % ± SE 20.5 ± 0.682 38.1 ± 5.01 < 0.001
Low HDL, % ± SE 47.2 ± 1.05 49.5 ± 4.7 < 0.001
Hypertriglyceridemia, % ± SE 48.5 ± 1.022 82.3 ± 2.91 < 0.001
Metabolic Syndrome, % ± SE 42.6 ± 1.042 91.4 ± 2.61 < 0.001
Platelet count (1000 cells/uL), mean ± SE 261.4 ± 1.22 243.1 ± 5.71 0.007
ALT (U/L), mean ± SE 38.2 ± 0.322 53.1 ± 3.61 < 0.001
AST (U/L), mean ± SE 31.2 ± 0.342 43.3 ± 3.31 < 0.001
Alkaline phosphatase (U/L), mean ± SE 71.4 ± 0.51 76.7 ± 3.4 0.01
Total bilirubin (mg/dL), mean ± SE 0.72 ± 0.01 0.77 ± 0.02 0.007
Creatinine (mg/dL), mean ± SE 0.86 ± 0.00 0.86 ± 0.01 0.15
Cholesterol (mg/dL), mean ± SE 206.8 ± 0.792 224.7 ± 4.31 < 0.001
Triglycerides (mg/dL), mean ± SE 186.6 ± 2.82 268.0 ± 17.21 < 0.001
HDL (mg/dL), mean ± SE 48.3 ± 0.30 48.3 ± 1.7 < 0.001
LDL (mg/dL), mean ± SE 121.2 ± 0.71 122.8 ± 4.8 < 0.001
Gamma glutamyl transferase (U/L), mean ± SE 36.6 ± 0.622 94.6 ± 16.41 0.002
Glycohemoglobin (%), mean ± SE 5.6 ± 0.02 5.7 ± 0.09 < 0.001
FIB-4, mean ± SE 0.94 ± 0.012 1.2 ± 0.091 0.001
FIB-4 > 2.67, % ± SE 1.7 ± 0.22 7.1 ± 2.5 0.045
Population weighted means or percentages are presented with corresponding SE.
1Significantly different from NAFLD;
2Significantly different from BAFLD. Post-hoc comparisons were done using Bonferroni correction. NAFLD:
Non-alcoholic fatty liver disease; BAFLD: Both alcoholic and non-alcoholic fatty liver disease; BMI: body
mass index;  HTN: Hypertension;  HDL: High density lipoprotein;  LDL: Low density lipoprotein;  ALT:
Alanine aminotransferase; AST: Aspartate aminotransferase; FIB-4: Fibrosis-4.
national database; thus, chronological relationships could not be established. The use
of elevated ALT and BMI to define patients with NAFLD is imperfect and may have
included patients who do not actually have NAFLD and excluded lean subjects that
have non-obese NAFLD. However, given the large population-based study sample,
we considered this definition to be the most suitable for this study. We used the non-
invasive fibrosis score to predict AF which has been previously used in NHANES
studies, as it was impossible to perform liver biopsies or even fibro-scans in such a
large cohort[34]; however, it is not the gold-standard. We did not use the AST/ ALT
ratio or aspartate aminotransferase to platelet ratio index (APRI) to diagnose AF given
their  heavy reliance  on  AST values,  which  are  known to  be  affected  by  alcohol
consumption. Similarly, we did not use the NAFLD fibrosis score because diabetes is
one of its components and this may have biased our estimates of AF. Using a large,
national, population-based sample allows for the ability to generalize our results to
the United States population and offsets these limitations.
In conclusion, a substantial percentage of the general American population may
have BAFLD. Patients with BAFLD tend to have more advanced disease and may
have a higher risk of progression to cirrhosis or end-stage liver disease. Therefore,
future research should aim to identify the burden of liver disease in this population
and intervene in  a  timely fashion.  The risk of  the combined effects  of  MetS and
alcohol consumption should be taken seriously in all patients with suspected NAFLD.
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Figure 1
Figure 1  The prevalence of advanced fibrosis in patients with non-alcoholic fatty liver disease (1.7%) and
both alcoholic and non-alcoholic fatty liver disease (7.1%). Patients with BAFLD have 3-fold increase in the
prevalence of advanced fibrosis. NAFLD: Non-alcoholic fatty liver disease; BAFLD: Both alcoholic and non-alcoholic
fatty liver disease; AF: Advanced fibrosis.
Importantly, screening for risky, often under-reported, alcohol consumption should
be considered. Data on safe alcohol consumption in NAFLD is conflicting and needs
further assessment in future prospective studies.
ARTICLE HIGHLIGHTS
Research background
Fatty liver disease caused by excess alcohol consumption is called alcoholic liver disease (ALD)
whereas fatty liver disease caused by metabolic disease is called non-alcoholic fatty liver disease
(NAFLD). Often, risk factors for both types of fatty liver diseases occur in the same individual,
especially as the prevalence of both of these diseases is on the rise. The presence of both types of
fatty liver disease in one individual may lead to the development of a new condition we call both
alcoholic and NAFLD (BAFLD). We believe that patients with BAFLD are at a higher risk of
advanced  fibrosis  and  complications  related  to  end-stage  liver  disease.  Studying  and
understanding BAFLD has important public health and policy implications.
Research motivation
A new fatty liver entity, we call BAFLD, occurs when both ALD and NAFLD risk factors are
present in the same individual. We reported on the clinical characteristics and degree of liver
fibrosis in BAFLD patients compared to NAFLD patients. As most of the risk factors that lead to
BAFLD are modifiable dietary and lifestyle choices, understanding their reciprocal interaction
and combined effect on the liver might lead to a better understanding of BAFLD pathogenesis,
treatment, and prevention. This has important public health and policy implications.
Research objectives
This study aimed to identify the prevalence of NAFLD and BAFLD and to assess the clinical
characteristics of patients with BAFLD in comparison to those with NAFLD in a large cohort of
subjects in the United States.
Research methods
This is a cross-sectional study that was done using National Health and Nutrition Examination
Survey between 2003-2014.  NAFLD and BAFLD patients  were identified.  Univariable  and
multivariable analysis were performed to assess differences between NAFLD and BAFLD and to
compare severity based on a validated fibrosis score (FIB4 index).
Research results
The prevalence of NAFLD was at 25.9% and that of BAFLD was 0.84% which corresponds to an
estimated 1.24 million Americans affected by BAFLD. Compared to NAFLD, patients with
BAFLD were more likely to be male, smokers, have higher ALT, AST, triglycerides, and lower
platelets;  P  <  0.01 for  all.  More importantly,  after  adjusting for  MetS components,  BAFLD
patients were significantly about three times more likely to have advanced fibrosis based on FIB4
index > 2.67, P = 0.004].
Research conclusions
In conclusion, a substantial percentage of the general American population may have BAFLD.
Patients  with  BAFLD tend to  have more  advanced disease  and may have a  higher  risk  of
progression to cirrhosis and end-stage liver disease. Therefore, special attention should be paid
to this population to identify the burden of liver disease and intervene in a timely fashion.
Research perspectives
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The possibility of the combined effects of MetS and alcohol consumption should be considered in
all  patients  with  suspected  NAFLD.  Vitally,  consideration  should  be  given  to  the  role  of
screening for identification of risky, often under-reported, alcohol consumption. Data on safe
alcohol consumption in NAFLD is conflicting and needs further assessment in future prospective
studies.
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